News – Rare Access Action Project

Comments in response to MACPAC’s recent recommendations for the 2021 Congressional report

On behalf of the Rare Access Action Project (RAAP), we appreciate the opportunity to submit the following comments in response to MACPAC’s recent recommendations for the 2021...Read More

Medicare Part D: A Sledgehammer On A Fragile Market, When A Scalpel Is Needed

When is the last time anyone heard of a government program not only working well, but also coming in under budget? Yet that is the reality of Medicare Part D, a market-driven program that...Read More

Efforts to Cut Drug Prices Would Harm Rare-Disease Patients

Government policy changes sometimes have all the subtlety of a steam roller, barreling forward without sufficient regard for everything in its path. Such is the case today with proposed changes...Read More

Rare Access Action Statement on HR 3

On April 22nd, 2021, the House reintroduced Elijah E. Cummings Lower Drug Costs Now Act (H.R. 3) to address the affordability of drugs and biologicals in the United States, which includes the...Read More

Rare Disease Drug Market May be Devastated by Current Proposed Changes to Medicare D, finds the Rare Access Action Project

The Rare Access Action Project (RAAP) announced results of a devastating report conducted on the impact of proposed change to Medicare D to companies that develop treatments for Rare Diseases,...Read More

In The News

For press inquiries, please click below:

Comments in response to MACPAC’s recent recommendations for the 2021 Congressional report

Medicare Part D: A Sledgehammer On A Fragile Market, When A Scalpel Is Needed

Efforts to Cut Drug Prices Would Harm Rare-Disease Patients

Rare Access Action Statement on HR 3

Rare Disease Drug Market May be Devastated by Current Proposed Changes to Medicare D, finds the Rare Access Action Project

Former Congressman Matt Salmon To Join RAAP

Rare Disease Patients Need Access To Therapy Innovations

Changes in Medicare Part D Benefit Design Can Impact Availability of Future Treatments

Let's Start a Conversation